Onic myeloid leukemia in chronic phase working with molecular finish points: tyrosine kinase inhibitor optimization and selectivity study. J Clin Oncol. 2010;28(3): 424?30. 25. Saglio G, Kim DW, Issaragrisil S, et al; ENESTnd Investigators. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010;362(24):2251?259. 26. Baccarani M, Cortes J, Pane F, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol. 2009;27(35):6041?051. 27. Shah NP, Kasap C, Weier C, et al. Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis. Cancer Cell. 2008;14(6):485?93. 28. Marin D, Bazeos A, Mahon FX, et al. Adherence would be the crucial factor for achieving molecular responses in sufferers with chronic myeloid leukemia who realize complete cytogenetic responses on imatinib. J Clin Oncol. 2010;28(14):2381?388. 29. Ibrahim AR, Eliasson L, Apperley JF, et al. Poor adherence may be the key explanation for loss of CCyR and imatinib failure for chronic myeloid leukemia individuals on long-term therapy. Blood. 2011;117(14): 3733?736. 30. Kantarjian H, Sawyers C, Hochhaus A, et al; for the International STI571 CML Study Group. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 2002;346(9):645?52. 31. Rosti G, Iacobucci I, Bassi S, et al. Effect of age around the outcome of sufferers with chronic myeloid leukemia in late chronic phase: final results of a phase II study with the GIMEMA CML Operating Celebration.Tetrahydroxydiboron web Haematologica. 2007;92(1):101?05. 32. Rousselot P, Boucher S, Etienne G, et al. Pharmacokinetics of dasatinib as a 1st line therapy in newly diagnosed CML sufferers (OPTIM dasatinib trial): correlation with security and response [Abstract]. Blood. 2010;116(21):3432. 33. Eley T, Luo FR, Agrawal S, et al. Phase I study with the impact of gastric acid pH modulators on the bioavailability of oral dasatinib in healthful subjects.4,4′,4”,4”’-Methanetetrayltetraaniline custom synthesis J Clin Pharmacol.PMID:23357584 2009;49(6):700?09.Squibb, Novartis, and Ariad. The authors report no other conflicts of interest.
ONCOLOGY LETTERS 7: 50-52,Sustained total response of hepatocellular carcinoma with portal vein tumor thrombus following discontinuation of sorafenib: A case reportKAZUE SHIOZAWA, MANABU WATANABE, TAKASHI IKEHARA, YASUSHI MATSUKIYO, MICHIO KOGAME, MASAHIRO KANAYAMA, TEPPEI MATSUI, YOSHINORI KIKUCHI, KOJI ISHII, YOSHINORI IGARASHI and YASUKIYO SUMINO Division of Gastroenterology and Hepatology, Department of Internal Medicine, Toho University Medical Center, Omori Hospital, Ota-ku, Tokyo 143-8541, Japan Received April 25, 2013; Accepted October 29, 2013 DOI: ten.3892/ol.2013.1664 Abstract. Hepatocellular carcinoma (HCC) will be the third most common cause of cancer-associated mortality worldwide. No powerful therapy has been established for unresectable sophisticated HCC, and the prognosis is poor. Sorafenib is an oral multi-targeted tyrosine kinase inhibitor for unresectable advanced HCC that drastically improves progressionfree and all round survival. Even so, inside the two huge phase III clinical trials (the SHARP and AsiaPacific trials), no situations of comprehensive response (CR) were reported. The present study reports the case of a 68-year-old male with hepatitis C virus-related cirrhosis and several recurrent HCCs, having a tumor thrombus of the third portal vein following resection. The patient received 400 mg when day-to-day (half the common dose) of sorafenib for two ye.